PMDA: English version of the global principles for clinical trials revised
Japan's PMDA (Pharmaceuticals and Medical Devices Agency) published changes to its principles for global clinical trials late last year. This revised document was published in English at the end of April 2022.
The PMDA thereby clarifies its intention to promote global clinical trials with Japanese participation. The revised sections of the document are highlighted.
The updates relate to the evaluation of the long-term safety of drugs and the number of study participants required to test a drug, for the long-term treatment of a non-fatal disease. The revised document, unlike last December's version, states that consideration of the results of global clinical trials of the drug in question is also acceptable if insufficient data to be collected due to too few Japanese participants and subjects.
The safety assessment can be collected using data from international trials with Japan's participation, as long as the results do not show a clear difference between Japanese and non-Japanese enrollees.
Source:
Meet the GMP Compliance Adviser
The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.
The demo access is non-binding and ends automatically.
You may also be interested in the following articles:
